Results 61 to 70 of about 3,153,687 (368)

MACC1 Is Associated With Epithelial–Mesenchymal Transition and Can Predict Poor Prognosis in Nasopharyngeal Carcinoma

Frontiers in Oncology, 2021
BackgroundGiven the reported correlation between the oncogene metastasis-associated in colon cancer 1 (MACC1) and nasopharyngeal carcinoma (NPC), as well as between MACC1 and epithelial–mesenchymal transition (EMT), we speculated that EMT is a likely ...
Hao Cheng, Hao Cheng, Linxiang Zhou, Yalan Long, Juanjuan Xiang, Longhua Chen   +5 more
doaj   +1 more source

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

New England Journal of Medicine, 2007
BACKGROUND Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovačević, V. Lesovoy, I. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R. Motzer   +18 more
semanticscholar   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma

Frontiers in Oncology, 2020
BackgroundTo compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus induction chemotherapy plus radiotherapy (IC+RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).Patients and ...
Sai-Lan Liu, Sai-Lan Liu, Xue-Song Sun, Xue-Song Sun, Zi-Jian Lu, Zi-Jian Lu, Qiu-Yan Chen, Qiu-Yan Chen, Huan-Xin Lin, Huan-Xin Lin, Lin-Quan Tang, Lin-Quan Tang, Jin-Xin Bei, Ling Guo, Ling Guo, Hai-Qiang Mai, Hai-Qiang Mai   +16 more
doaj   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

The mediating role of loneliness between psychological resilience and health-related quality of life among patients with nasopharyngeal carcinoma: a cross-sectional study using structural equation modeling

BMC Psychiatry
Background Cancer patients’ health-related quality of life (HRQoL) has always been a hot discussion spot. Loneliness and psychological resilience are considered to be significant psychosocial factors impacting the HRQoL of the cancer population. However,
Mengna Luo, Siting Lin, Zhenxiu Li, Liping Wu, Linmin Chen, Qiulan Yang, Yuying Fan   +6 more
doaj   +1 more source

Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway [PDF]

Iranian Journal of Basic Medical Sciences, 2016
Objective(s): Renal cell carcinoma (RCC) is insensitive to conventional chemotherapy. Ginkgetin effectively treats several carcinoma cells. However, little is known about effects of Ginkgetin on RCC.
Yu Ren, Shuang-shuang Huang, Xue Wang, Zhong-guan Lou, Xu-ping Yao, Guo-bin Weng   +5 more
doaj   +1 more source

Integrated Genomic Analyses of Ovarian Carcinoma

Nature, 2011
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter ...
D. Bell, A. Berchuck, M. Birrer, J. Chien, D. Cramer, F. Dao, R. Dhir, P. Disaia, H. Gabra, Pat Glenn, A. Godwin, J. Gross, L. Hartmann, M. Huang, D. Huntsman, M. Iacocca, M. Imieliński, S. Kalloger, B. Karlan, D. Levine, G. Mills, C. Morrison, D. Mutch, Narciso Olvera, S. Orsulic, K. Park, N. Petrelli, B. Rabeno, J. Rader, B. Sikic, K. Smith-McCune, A. Sood, D. Bowtell, R. Penny, J. Testa, K. Chang, H. Dinh, J. Drummond, G. Fowler, P. Gunaratne, A. Hawes, C. Kovar, L. Lewis, M. Morgan, I. Newsham, J. Santibanez, J. Reid, L. Treviño, Y. Wu, M. Wang, D. Muzny, D. Wheeler, R. Gibbs, G. Getz, M. Lawrence, K. Cibulskis, A. Sivachenko, C. Sougnez, Douglas Voet, Jane Wilkinson, Toby Bloom, K. Ardlie, T. Fennell, J. Baldwin, S. Gabriel, E. Lander, L. Ding, R. Fulton, D. Koboldt, M. McLellan, T. Wylie, Jason R. Walker, M. O'Laughlin, D. Dooling, L. Fulton, R. Abbott, N. Dees, Q. Zhang, C. Kandoth, M. Wendl, W. Schierding, D. Shen, C. Harris, H. Schmidt, Joelle Kalicki, K. Delehaunty, C. Fronick, Ryan T. Demeter, L. Cook, J. Wallis, L. Lin, V. Magrini, J. Hodges, James M. Eldred, S. M. Smith, C. Pohl, Fabio Vandin, Benjamin J. Raphael, G. Weinstock, E. Mardis, R. Wilson, M. Meyerson, W. Winckler, R. Verhaak, Suzie Carter, C. Mermel, G. Saksena, H. Nguyen, R. Onofrio, D. Hubbard, S. Gupta, A. Crenshaw, A. Ramos, L. Chin, A. Protopopov, Juinhua Zhang, T. Kim, I. Perna, Y. Xiao, Hailei Zhang, G. Ren, N. Sathiamoorthy, R. Park, E. Lee, P. Park, R. Kucherlapati, D. Absher, L. Waite, G. Sherlock, J. Brooks, Jun Li, Jin Xu, R. Myers, P. Laird, L. Cope, J. Herman, Hui Shen, D. Weisenberger, H. Noushmehr, F. Pan, T. Triche, B. Berman, D. V. Berg, J. Buckley, S. Baylin, P. Spellman, E. Purdom, P. Neuvial, H. Bengtsson, L. Jakkula, S. Durinck, J. Han, S. Dorton, H. Marr, Y. Choi, V. Wang, Ninghai Wang, J. Ngai, J. Conboy, B. Parvin, H. Feiler, T. Speed, J. Gray, N. Socci, Yanke Liang, B. Taylor, N. Schultz, L. Borsu, A. Lash, C. Brennan, A. Viale, C. Sander, M. Ladanyi, K. Hoadley, S. Meng, Y. Du, Yufeng Shi, Lulin Li, Y. Turman, D. Zang, E. Helms, S. Balu, X. Zhou, Jinhua Wu, M. D. Topal, D. Hayes, C. Perou, Jun Zhang, Chaowei Wu, S. Shukla, A. Sivachenko, R. Jing, Yueh-Feng Liu, M. Noble, H. Carter, D. Kim, R. Karchin, J. Korkola, Laura M. Heiser, R. Cho, Zhihao Hu, E. Cerami, A. Olshen, B. Reva, Yevgeniy Antipin, R. Shen, P. Mankoo, R. Sheridan, G. Ciriello, William K. Chang, J. Bernanke, D. Haussler, C. Benz, Joshua M. Stuart, S. Benz, J. Z. Sanborn, Charles J. Vaske, Jiangyu Zhu, C. Szeto, G. Scott, C. Yau, M. Wilkerson, N. Zhang, Rehan Akbani, K. Baggerly, W. Yung, J. Weinstein, T. Shelton, D. Grimm, M. Hatfield, S. Morris, P. Yena, P. Rhodes, M. Sherman, J. Paulauskis, S. Millis, A. Kahn, J. Greene, R. Sfeir, M. Jensen, James K. Chen, J. Whitmore, S. Alonso, J. Jordan, A. Chu, Jinghui Zhang, A. Barker, C. Compton, G. Eley, M. Ferguson, P. Fielding, D. Gerhard, R. Myles, C. Schaefer, K. Shaw, J. Vaught, J. Vockley, P. Good, M. Guyer, B. Ozenberger, James Peterson, E. Thomson   +261 more
semanticscholar   +1 more source

CARCINOMA OF THE DUODENUM

Annals of Surgery, 1920
n ...
McGoire, Edgar R., Cornish, Percy G.
openaire   +4 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source